[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 9, 2005

Ribavirin and Use of Clotting Factors in Patients With Hemophilia and Chronic Hepatitis C

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(10):1187-1192. doi:10.1001/jama.293.10.1190-c

To the Editor: Ribavirin has been used in combination with interferon (IFN) alfa to treat chronic hepatitis C. This combination therapy has been reported to be more effective than IFN monotherapy for eradicating hepatitis C virus (HCV),13 including that occurring in patients with concomitant hemophilia.4,5 We are unaware of previous reports of reduction in the use of clotting factors in HCV-positive patients with hemophilia treated with ribavirin and IFN.

First Page Preview View Large
First page PDF preview
First page PDF preview
×